Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and...

issues affecting payer uptake and provider adoption of biosimilars in the US, such as economic considerations, clinical evidence, and market

Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, discussed the FDA approvals of new drugs and pricing.

In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline.

Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs,...

Learn about promising drugs currently in the pharmaceutical pipeline and the impact of FDA interventions from IPD presenters.

Several drug manufacturers have announced price cuts on commonly prescribed insulin products. By Brock Bizzell and David Baker | Original...

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs...

IPD Analytics speaks about key takeaways from the AJMC 2024 Annual Conference

IPD presents at the AMCP 2024 annual meeting discussing the current promise and future potential of gene and cell therapies.

IPD Analytics LLC. discusses the up to 50 generics that could be approved this year, including Victoza to treat patients with diabetes.

Jeffrey Casberg of IPD Analytics LLC, talks about how payers are thinking about weight-loss drugs.

A CPO in the C-suite determines how a health system can move from a cost center to a revenue center with healthy operating margins

Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory...

Explore the evolving landscape of biosimilars in the US market, from legislative influences to industry challenges, with expert insights.

Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster.

The U.S. market for specialty generic drugs hit $23 billion in 2021, and is expected to reach nearly $43 billion by 2027, driven by the...

A wave of blockbuster generic drugs launches, new brand drugs that address unmet needs, and legislation that would bring transparency to...

The Centers for Medicare and Medicaid Services (CMS) has released the list of the first 10 drugs to be negotiated under the Inflation...

We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior...